QbD-driven RP-HPLC method for novel chemo-herbal combination, in-silico, force degradation studies, and characterization of dual drug-loaded polymeric and lipidic nanocarriers

被引：0
作者：
Ankaj Kumar
Sandeep Jat
Pramod Kumar
Arvind Gulbake
机构：
[1] National Institute of Pharmaceutical Education and Research Guwahati,Department of Pharmaceutics
[2] National Institute of Pharmaceutical Education and Research Guwahati,Department of Pharmaceutical Analysis
来源：
Future Journal of Pharmaceutical Sciences | / 9卷
关键词：
Lenvatinib; Biochanin A; RP-HPLC; HRMS; PLGA NPs; Cubosomes; Zeneth; Design of experiment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The RP-HPLC method was developed for a multiple tyrosine kinase inhibitor (MTKI), lenvatinib (LTB), and an isoflavone called biochanin A (BCA), employing Box–Behnken design (BBD).A total of 41.17% and 70.58% degradants were quantified through experimental investigation (RP-HPLC and HRMS) for LTB and BCA in contrast to in silico predicted degradants.In-silico toxicity assessment for LTB, BCA, and their degradants explains the necessity of conducting degradation studies during drug development.Finally, the applications of the developed RP-HPLC method for the development of chemo-herbal drug nanocarriers (polymeric and lipidic) were studied.
引用
收藏
相关论文
共 128 条
  • [1] Okem A(2022)A review of the pharmacodynamic effect of chemo-herbal drug combinations therapy for cancer treatment Med Drug Discov 17 100147-243
  • [2] Henstra C(2018)Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy J Control Release 285 230-2400
  • [3] Lambert M(2022)Green self-assembled lactoferrin carboxymethyl cellulose nanogels for synergistic chemo/herbal breast cancer therapy Colloids Surf B Biointerfaces 217 112657-3860
  • [4] Hayeshi R(2013)Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance Biomaterials 35 2391-33
  • [5] Elgohary M(2021)Self-assembled phospholipid-based mixed micelles for improving the solubility, bioavailability and anticancer activity of lenvatinib Colloids Surf B Biointerfaces 201 111644-1124
  • [6] Helmy M(2013)Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer Br J Cancer 11 3847-26
  • [7] Abdelfattah E-Z(2019)Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial Lancet Oncol 46 1-2836
  • [8] Atallah M(2019)Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment Cancer Manag Res 16 100358-1392
  • [9] Sallam M(2019)Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways Exp Ther Med 149 105352-441
  • [10] Abdelmoneem M(2020)Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy Drug Dev Ind Pharm 6 30717-225
12345678910